Atherosclerosis:美360万人研究:便秘及用通便药增加心血管病和死亡风险

2019-01-04 朱柳媛 中国循环杂志

既往研究表明,便秘与动脉粥样硬化有关,可能机制是便秘导致肠道微生物发生变化。

既往研究表明,便秘与动脉粥样硬化有关,可能机制是便秘导致肠道微生物发生变化。

近期发表的一项覆盖全美近360万退伍军人的研究进一步发现,便秘以及用通便药都会增加全因死亡和血管病发生风险。

在该研究中,校正了人口统计资料、合并症、用药情况和社会经济状态等因素后,7年多随访期间,便秘者的全因死亡风险较没有便秘者增加了12%,冠心病和缺血性脑卒中发生风险也分别升高11%和19%。

另外,与从未用通便药的人相比,应用1次、≥2次通便药的人全因死亡的风险分别增加15%和14%,冠心病发生风险分别增加11%和10%,缺血性脑卒中发生风险分别增加19%和21%。

在该研究中,便秘根据临床诊断标准或应用通便药来确定。7.1%的人存在便秘。

原始出处:
Keiichi Sumida, et al. Constipation and risk of death and cardiovascular events. Atherosclerosis, Published online: December 23, 2018.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1644724, encodeId=0ab91644e2491, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Apr 28 18:16:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947332, encodeId=7d8a194e33288, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Thu Nov 07 21:16:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358526, encodeId=ddf335852682, content=好多东西都拿来研究,只有想不到没有做不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 14:05:40 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358047, encodeId=227735804ece, content=心血管疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Jan 13 17:02:54 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255820, encodeId=7a711255820b4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 06 13:16:00 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364437, encodeId=4e69136443e5b, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jan 06 13:16:00 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1644724, encodeId=0ab91644e2491, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Apr 28 18:16:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947332, encodeId=7d8a194e33288, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Thu Nov 07 21:16:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358526, encodeId=ddf335852682, content=好多东西都拿来研究,只有想不到没有做不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 14:05:40 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358047, encodeId=227735804ece, content=心血管疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Jan 13 17:02:54 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255820, encodeId=7a711255820b4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 06 13:16:00 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364437, encodeId=4e69136443e5b, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jan 06 13:16:00 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1644724, encodeId=0ab91644e2491, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Apr 28 18:16:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947332, encodeId=7d8a194e33288, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Thu Nov 07 21:16:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358526, encodeId=ddf335852682, content=好多东西都拿来研究,只有想不到没有做不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 14:05:40 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358047, encodeId=227735804ece, content=心血管疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Jan 13 17:02:54 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255820, encodeId=7a711255820b4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 06 13:16:00 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364437, encodeId=4e69136443e5b, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jan 06 13:16:00 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
    2019-01-18 佳虎

    好多东西都拿来研究,只有想不到没有做不到

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1644724, encodeId=0ab91644e2491, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Apr 28 18:16:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947332, encodeId=7d8a194e33288, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Thu Nov 07 21:16:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358526, encodeId=ddf335852682, content=好多东西都拿来研究,只有想不到没有做不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 14:05:40 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358047, encodeId=227735804ece, content=心血管疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Jan 13 17:02:54 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255820, encodeId=7a711255820b4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 06 13:16:00 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364437, encodeId=4e69136443e5b, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jan 06 13:16:00 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
    2019-01-13 jyzxjiangqin

    心血管疾病治疗。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1644724, encodeId=0ab91644e2491, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Apr 28 18:16:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947332, encodeId=7d8a194e33288, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Thu Nov 07 21:16:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358526, encodeId=ddf335852682, content=好多东西都拿来研究,只有想不到没有做不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 14:05:40 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358047, encodeId=227735804ece, content=心血管疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Jan 13 17:02:54 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255820, encodeId=7a711255820b4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 06 13:16:00 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364437, encodeId=4e69136443e5b, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jan 06 13:16:00 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1644724, encodeId=0ab91644e2491, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Apr 28 18:16:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947332, encodeId=7d8a194e33288, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Thu Nov 07 21:16:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358526, encodeId=ddf335852682, content=好多东西都拿来研究,只有想不到没有做不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 14:05:40 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358047, encodeId=227735804ece, content=心血管疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Jan 13 17:02:54 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255820, encodeId=7a711255820b4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 06 13:16:00 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364437, encodeId=4e69136443e5b, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jan 06 13:16:00 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
    2019-01-06 lsndxfj

相关资讯

Lancet Gastroen Hepatol:家庭开展排便失调生物反馈疗法的可能性研究

基于门诊的生物反馈疗法是治疗便秘伴排便失调症的有效方法,目前由专业医生进行,而且需要多次治疗。近日研究人员考察了在家庭内开展生物反馈疗法的可能性。18-80岁的符合Rome III标准的功能性便秘伴排便失调患者参与研究,随机接受门诊或家庭内生物反馈疗法,门诊疗法为治疗师指导下的盆底训练,每2周1次,为期3个月。家庭疗法为20分钟的自我训练课程,每天2次,使用自插入探针提供视觉反馈,通过手持监测装置

NEJM:慢性铅中毒的Burton线-病例报道

Burton线是慢性铅中毒的标志,当铅与口腔细菌代谢产物发生反应时就会形成这种标志。然后患者承认有10年的咀嚼鸦片史。对患者的鸦片样本进行分析,发现每1g鸦片中铅浓度为17mg。铅有时可能会添加到鸦片中以增加其重量。

2018 AGA指南:阿片类药物引起便秘的医学管理

2018年10月,美国胃肠病协会(AGA)发布了阿片类药物引起便秘的医学管理指南,指南针对阿片类药物引起便秘的医学管理提出了官方建议,涉及泻药、外周作用μ阿片类受体拮抗剂,肠促分泌素以及选择性5-HT激动剂的应用。

当糖尿病遇上便秘,该如何是好?

糖尿病容易合并便秘,尤其多见于血糖控制不佳与老年糖尿病患者。便秘可能会导致糖尿病患者眼底出血、失明及心衰。糖尿病患者便秘的原因很多,应查清原因,在医师指导下改善生活方式,合理用药。

便秘竟会导致瘫痪!吓得我菊花一紧…

便秘(constipation)是一种临床常见病症,表现为排便次数减少、粪便干硬和(或)排便困难,排便次数减少指每周排便少于3次,排便困难包括排便费力、排便不尽感、排便费时以及需手法辅助。从全球范围看,成年人中位患病率为16%(0.7%~79%),60岁以上的老年人患病率为33.5%,男女患病比例约为1∶1.5,而我国功能性便秘的患病率为6%,男女患病比例为1∶2。事情是这样的据英国《独立报》6

糖尿病患者便秘了,能开乳果糖吗?

科里30床的老大娘经常出些难题为难我们,篇幅有限就不一一举例说明了。临床医生大概都经历过,就是那种各种提要求的患者,把医院当成宾馆,医生当成是服务员。不是医生指导患者如何治疗,而是她自己想怎么治疗就怎么治疗。